Hepatitis C Virus
Presidio Pharmaceuticals, Inc. Selects Second Clinical Candidate from Hepatitis C Virus NS5A Inhibitor Program
Published in Hepatitis Weekly, June 7th, 2010
Inhibitors of the HCV NS5A protein represent an exciting, highly potent class that is distinct from other classes of HCV antivirals that target the viral protease or replicase. With poor response and tolerance issues associated with the current standard of care treatment-pegylated-IFN and ribavirin-there is clear need for more potent and better tolerated inhibitors that can...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2010-06-07)
More Articles from Hepatitis Weekly
- Hepatitis B Antigens
Reports summarize hepatitis b antigens study results from T. Nguyen and co-researchers - Chronic Hepatitis B Virus
New chronic hepatitis B virus study results reported from Chang Gung University, Department of Internal Medicine - Hepatitis
Data from China Agricultural University provide new insights into hepatitis - Hepatitis B Virus
Data on hepatitis B virus detailed by researchers at University of California - Hepatitis B Virus
Investigators at Austin Hospital target hepatitis B virus - Hepatitis B Virus
Investigators at Nankai University have published new data on hepatitis B virus - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
